Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Stewart Enterprises, Inc. (STEI), Smithfield Foods, Inc. (SFD), The Fresh Market Inc (TFM) & More: Are These Stocks Worth Buying?

We will take a quick look at four stocks that have had substantial rises in price so far today. The four stocks we will review are: Stewart Enterprises, Inc. (NASDAQ:STEI), Smithfield Foods, Inc. (NYSE:SFD), The Fresh Market Inc (NASDAQ:TFM) and  Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)

Stewart Enterprises, Inc. (NASDAQ:STEI) is up over 34% currently, to trade at $13.36; this is the new 52-week high. The company has just announced a definitive merger agreement with Service Corporation International (NYSE:SCI), which will allow SCI to acquire Stewart for approximately $1.4 billion in cash. Stewart Enterprises, Inc. (NASDAQ:STEI) has been in significant uptrend since mid-April, perhaps on insider knowledge of this corporate event. Pre-merger Stewart Enterprises, Inc. (NASDAQ:STEI) is the 2nd largest funeral and cemetery services company in the US.

Smithfield Foods, Inc. (NYSE:SFD)

Smithfield Foods, Inc. (NYSE:SFD) is up over 25% as of writing, trading at $32.46, a massive gap up from the close of $25.97 yesterday as well as being a new 52-week high. The owner of the Armour and Farmland brands announced today that it will be acquired by Chinese company Shuanghi Group. The Shuanghi Group has agreed to pay $34 a share for Smithfield Foods, Inc. (NYSE:SFD). The meat company has gained nearly 20% year to date.

Specialty grocer The Fresh Market Inc (NASDAQ:TFM) is up around 14.37% to $53.02 a share. The company posted a rise of 15% in fiscal first-quarter earnings early this morning, as well as raising its same-stores sales growth estimate and confirming its earnings guidance. In February Goldman Sachs Group, Inc. (NYSE:GS) recently upped their recommendation on the stock to Buy, setting a 12-month price target of $60.

Finally, we consider Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), which is up 12.2% so far today, to trade at $68.15. The impetus for the rise seems to be an upgrade to the price target by JPMorgan Chase & Co. (NYSE:JPM) analysts this morning, from $48 to $69 per share. Aegerion develops the drug lomitapide, which treats people with homozygous familial hypercholesterolemia, or HoFH, a condition that causes very high cholesterol.

Disclosure: none